Premium
Significance of a new stratification of alkaline phosphatase and extent of disease in patients with prostate carcinoma with bone metastasis
Author(s) -
Imai Kyoichi,
Tomaru Yukio,
Ohnuki Takahisa,
Yamanaka Hidetoshi,
Sakai Hideki,
Kanetake Hiroshi,
Minami Yuzo,
Nomata Koichiro,
Saito Yutaka
Publication year - 1992
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19920615)69:12<2983::aid-cncr2820691220>3.0.co;2-1
Subject(s) - medicine , prostate cancer , bone scintigraphy , bone metastasis , alkaline phosphatase , grading (engineering) , metastasis , prostate , scintigraphy , oncology , bone disease , carcinoma , pathology , cancer , urology , radiology , osteoporosis , biochemistry , chemistry , civil engineering , engineering , enzyme
Bone is the most frequent site of metastatic prostate cancer and the prognosis of patients with bone metastasis is poor. The authors have investigated a semiquanti‐tative system to evaluate bone metastatic lesions in terms of cancer‐specific survival. Based on the extension of disease (EOD) grade proposed by Soloway and associates, a new EOD grading system obtained from bone scintig‐raphy alone and EOD score obtained from bone scintig‐raphy and alkaline phosphatase was studied in 164 patients with prostate cancer with metastatic bone involvement. In terms of a cancer‐specific survival and prostate cancer death, both the new EOD grade and the EOD score were apparently superior to eight other items studied (age, medical score, gait disturbance, histologic grade, erythrocyte sedimentation rate, prostatic acid phosphatase, and alkaline phosphatase). Multivariate analysis revealed that the EOD score was better than the new EOD grade. This improvement was due to the elimination of false‐positive or nonactive metastatic bone lesions on bone scintigraphy through the alkaline phosphatase evaluation.